Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 11 |
| List of Tables | 8 | 4 |
| List of Figures | 12 | 3 |
| CNS Disorder Therapeutic Market to 2017 - Introduction | 15 | 1 |
| GBI Research Report Guidance | 15 | 1 |
| CNS Disorder Therapeutic Market to 2017 - Global Market Overview | 16 | 9 |
| Introduction | 16 | 1 |
| Revenue | 17 | 1 |
| Generic Share | 18 | 1 |
| Annual Cost of Treatment | 19 | 1 |
| Top CNS Drug Products | 20 | 1 |
| Seroquel (IR/XR) (quetiapine fumarate) | 20 | 1 |
| Zyprexa (olanzapine) | 20 | 1 |
| Cymbalta (duloxetine Hcl) | 21 | 1 |
| Copaxone (glatiramer acetate) | 21 | 1 |
| Lyrica (pregabalin) | 22 | 1 |
| Abilify (aripiprazole) | 22 | 1 |
| Avonex (Interferon beta-1a) | 23 | 1 |
| Rebif (interferon beta-1a) | 23 | 1 |
| Effexor (venlafaxine) | 23 | 1 |
| Betaferon /Betaseron (Interferon beta-1b) | 24 | 1 |
| CNS Disorder Therapeutic Market to 2017 - Geographical Landscape | 25 | 8 |
| Revenue Analysis by Geography | 25 | 1 |
| The US | 26 | 1 |
| Revenue | 26 | 1 |
| Annual Cost of Treatment | 27 | 1 |
| Top Five Countries of Europe | 28 | 1 |
| Revenue | 28 | 2 |
| Annual Cost of Treatment | 30 | 1 |
| Japan | 31 | 1 |
| Revenue | 31 | 1 |
| Annual Cost of Treatment | 32 | 1 |
| CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape | 33 | 105 |
| Introduction | 33 | 1 |
| Treatment Algorithm | 34 | 1 |
| Revenue | 35 | 3 |
| Generic Share | 38 | 1 |
| Annual Cost of Treatment | 39 | 1 |
| Treatment Usage Patterns | 40 | 1 |
| Diseased Population | 41 | 1 |
| Treatment Seeking Population | 41 | 1 |
| Diagnosis Population | 41 | 1 |
| Prescription Population | 41 | 1 |
| Geriatric Population Growth and Increased Life Expectancy | 42 | 1 |
| Expected Launch of New Drugs Will Drive the Alzheimer s disease Market In Future | 42 | 1 |
| Low Diagnosis Rate Reduces Number of Patients on AD Drug Therapy. | 43 | 1 |
| Slow Drug Development Programs and Recent Drug Failures Will Hamper Development of Promising Molecules. | 43 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) | 43 | 1 |
| Introduction | 43 | 1 |
| Treatment Algorithm | 44 | 1 |
| Revenue | 45 | 2 |
| Revenue by Country | 47 | 1 |
| Generic Share | 48 | 1 |
| Annual Cost of Treatment | 49 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Diseased Population | 51 | 1 |
| Treatment Seeking Population | 51 | 1 |
| Diagnosis Population | 51 | 1 |
| Prescription Population | 51 | 1 |
| Drivers and Barriers to ADHD Market | 52 | 1 |
| Drivers for ADHD Market | 52 | 1 |
| Increase in Diseased Population | 52 | 1 |
| Barriers for ADHD Market | 52 | 1 |
| Misdiagnosis of ADHD is a Growing Concern | 52 | 1 |
| Drug Side Effects and Alternative Options | 52 | 1 |
| Patent Expiries of Major Drugs | 53 | 1 |
| Bipolar Disorder | 53 | 1 |
| Introduction | 53 | 1 |
| Treatment Algorithm | 54 | 1 |
| Revenue | 55 | 1 |
| Revenue by Country | 56 | 1 |
| Generic Share | 57 | 1 |
| Annual Cost of Treatment | 58 | 1 |
| Treatment Usage Patterns | 59 | 1 |
| Diseased Population | 60 | 1 |
| Treatment Seeking Population | 60 | 1 |
| Diagnosis Population | 60 | 1 |
| Prescription Population | 60 | 1 |
| Drivers and Barriers to Bipolar Disorder Market | 61 | 1 |
| Drivers for Bipolar Disorder Market | 61 | 1 |
| Increase in Patient Volume May Drive Market Growth in Future | 61 | 1 |
| Barriers for Bipolar Disorder Market | 61 | 1 |
| Patent Expiries of the Leading Anticonvulsants and Upcoming Patent Expiries of Antipsychotics | 61 | 1 |
| Low Diagnosis Rate of Bipolar Disorder | 61 | 1 |
| Prescription Rates are Higher for Lithium | 62 | 1 |
| Diabetic Neuropathy | 62 | 1 |
| Introduction | 62 | 1 |
| Treatment Algorithm | 63 | 1 |
| Revenue | 64 | 1 |
| Revenue by Country | 65 | 1 |
| Generic Share | 66 | 1 |
| Annual Cost of Treatment | 67 | 1 |
| Treatment Usage Pattern | 68 | 1 |
| Diseased Population | 69 | 1 |
| Treatment Seeking Population | 69 | 1 |
| Diagnosis Population | 69 | 1 |
| Prescription Population | 69 | 1 |
| Drivers and Restraints to Diabetic Neuropathy Market | 70 | 1 |
| Drivers for Diabetic Neuropathy Market | 70 | 1 |
| Expected Launch of New Molecules Will Drive the Diabetic Neuropathy Therapeutics Market Growth in Future | 70 | 1 |
| Increasing Diseased Population | 70 | 1 |
| Restraints for the Diabetic Neuropathy Therapeutics Market | 70 | 1 |
| Patent Expiry of Drugs Such as Cymbalta and Lyrica | 70 | 1 |
| Epilepsy | 71 | 1 |
| Introduction | 71 | 1 |
| Treatment Algorithm | 71 | 1 |
| Revenue | 72 | 1 |
| Revenue by Country | 73 | 1 |
| Generic Share | 74 | 1 |
| Annual Cost of Treatment | 75 | 1 |
| Treatment Usage Patterns | 76 | 1 |
| Diseased Population | 77 | 1 |
| Treatment Seeking Population | 77 | 1 |
| Diagnosis Population | 77 | 1 |
| Prescription Population | 77 | 1 |
| Drivers and Barriers to Epilepsy Market | 78 | 1 |
| Drivers for Epilepsy Market | 78 | 1 |
| Expected Launch of New Drugs Will Drive the Epilepsy Market | 78 | 1 |
| Rise in Geriatric Population | 78 | 1 |
| Barriers to Epilepsy Market | 78 | 1 |
| Patent Expiry of the Leading Anticonvulsants | 78 | 1 |
| Insomnia | 79 | 1 |
| Introduction | 79 | 1 |
| Treatment Algorithm | 80 | 1 |
| Revenue | 81 | 1 |
| Revenue by Country | 82 | 1 |
| Generic Share | 83 | 1 |
| Annual Cost of Treatment | 84 | 1 |
| Treatment Usage Patterns | 85 | 1 |
| Diseased Population | 86 | 1 |
| Treatment Seeking Population | 86 | 1 |
| Diagnosis Population | 86 | 1 |
| Prescription Population | 86 | 1 |
| Drivers and Barriers to Insomnia Market | 87 | 1 |
| Drivers for Insomnia Market | 87 | 1 |
| Aging population | 87 | 1 |
| High Increase in Obese Population | 87 | 1 |
| Barriers for Insomnia Market | 88 | 1 |
| Weak Pipeline Portfolio for Insomnia | 88 | 1 |
| Low Cost Treatments Suppress the Market | 88 | 1 |
| Migraine | 88 | 1 |
| Introduction | 88 | 1 |
| Treatment Algorithm | 89 | 1 |
| Revenue | 90 | 1 |
| Revenue by Country | 91 | 2 |
| Generic Share | 93 | 1 |
| Annual Cost of Treatment | 94 | 1 |
| Treatment Usage Patterns | 95 | 2 |
| Diseased Population | 97 | 1 |
| Treatment Seeking Population | 97 | 1 |
| Diagnosis Population | 97 | 1 |
| Prescription Population | 97 | 1 |
| Drivers and Barriers for Migraine Market | 98 | 1 |
| Drivers for Migraine Market | 98 | 1 |
| The Increasing Awareness Will Result in Increasing Prescription Rate | 98 | 1 |
| Barriers for Migraine Market | 99 | 1 |
| Low Treatment Seeking Behavior and Diagnosis Rate Restrain Growth in Prescription Population | 99 | 1 |
| Falling Prices of Migraine Treatment Will Restrain the Market by Off-setting the Impact of Increasing Volume | 99 | 1 |
| Multiple Sclerosis | 99 | 1 |
| Introduction | 99 | 2 |
| Treatment algorithm | 101 | 1 |
| Revenue | 102 | 2 |
| Revenue by Country | 104 | 1 |
| Generic Share | 105 | 1 |
| Annual Cost of Treatment | 106 | 1 |
| Treatment Usage Patterns | 107 | 1 |
| Diseased Population | 108 | 1 |
| Treatment Seeking Population | 108 | 1 |
| Diagnosis Population | 108 | 1 |
| Prescription Population | 108 | 1 |
| Drivers and Restraints to Multiple Sclerosis Therapeutics Market | 109 | 1 |
| Drivers for Multiple Sclerosis Market | 109 | 1 |
| Launch of Several High-priced Novel Disease-modifying Therapies | 109 | 1 |
| Increased Prescription Population | 109 | 1 |
| Restraints for Multiple Sclerosis Market | 110 | 1 |
| Patient Affordability and Reimbursement Issue | 110 | 1 |
| Patent Expiry of Major Drugs Is Expected to Cause Market Decline | 110 | 1 |
| Parkinson s Disease | 110 | 1 |
| Introduction | 110 | 1 |
| Treatment Algorithm | 111 | 1 |
| Revenue | 112 | 1 |
| Revenue by Country | 113 | 1 |
| Generic Share | 114 | 1 |
| Annual Cost of Treatment | 115 | 1 |
| Treatment Usage Patterns | 116 | 1 |
| Diseased Population | 117 | 1 |
| Treatment Seeking Population | 117 | 1 |
| Diagnosis Population | 117 | 1 |
| Prescription Population | 117 | 1 |
| Drivers and Restraints to Parkinson s Disease Therapeutics Market | 118 | 1 |
| Drivers for the Parkinson s disease Therapeutics Market | 118 | 1 |
| Rise in Geriatric Population and Increase in Life Expectancy | 118 | 1 |
| Restraints for the Parkinson s disease Therapeutics Market | 118 | 1 |
| Lack of Definite Diagnostic Techniques Delays Treatments of PD | 118 | 1 |
| Patent Expiry in Upcoming Years Will Affect the Market Growth | 118 | 1 |
| Schizophrenia | 119 | 1 |
| Introduction | 119 | 1 |
| Treatment Algorithm | 120 | 1 |
| Revenue | 121 | 1 |
| Revenue by Country | 122 | 1 |
| Generic Share | 123 | 1 |
| Annual Cost of Treatment | 124 | 1 |
| Treatment Usage Pattern | 125 | 1 |
| Diseased Population | 126 | 1 |
| Treatment Seeking Population | 126 | 1 |
| Diagnosis Population | 126 | 1 |
| Prescription Population | 126 | 1 |
| Drivers and Barriers to Schizophrenia Market | 127 | 1 |
| Drivers for Schizophrenia Market | 127 | 1 |
| Disease Population Growth | 127 | 1 |
| Expected Launch of Pipeline Molecules | 127 | 1 |
| Barriers for Schizophrenia Market | 128 | 1 |
| Low Treatment Seeking Behavior | 128 | 1 |
| Patent Expiries of Major Drugs | 128 | 1 |
| Major Depressive Disorder (MDD) | 128 | 1 |
| Introduction | 128 | 1 |
| Treatment Algorithm | 129 | 1 |
| Revenue | 130 | 1 |
| Revenue by Country | 131 | 1 |
| Generic Share | 132 | 1 |
| Annual Cost of Treatment | 133 | 1 |
| Treatment Usage Patterns | 134 | 1 |
| Diseased Population | 135 | 1 |
| Treatment Seeking Population | 135 | 1 |
| Diagnosis Population | 135 | 1 |
| Prescription Population | 135 | 1 |
| Drivers and Barriers to MDD Market | 136 | 1 |
| Drivers for MDD Market | 136 | 1 |
| New launches | 136 | 1 |
| Barriers for MDD Market | 136 | 1 |
| Non compliance to Drug Therapy and Side Effects of the Antidepressants | 136 | 1 |
| Misdiagnosis | 137 | 1 |
| Alternative Therapy for MDD | 137 | 1 |
| Central Nervous System Disorders Therapeutics Market to 2017 - Product Pipeline Analysis | 138 | 60 |
| Introduction | 138 | 1 |
| Product Pipeline by Indication | 138 | 1 |
| Product Pipeline by Clinical Stage of Development | 139 | 1 |
| Introduction | 140 | 10 |
| Attention Deficit Hyperactivity Disorder (ADHD) | 150 | 1 |
| Introduction | 150 | 3 |
| Bipolar Disorder | 153 | 1 |
| Introduction | 153 | 2 |
| Diabetic Neuropathy | 155 | 1 |
| Introduction | 155 | 2 |
| Epilepsy | 157 | 1 |
| Introduction | 157 | 4 |
| Insomnia | 161 | 1 |
| Introduction | 161 | 2 |
| Major Depressive Disorder (MDD) | 163 | 1 |
| Introduction | 163 | 4 |